India's anti-obesity drug market is entering a phase of moderate growth following a surge in generic semaglutide sales that began in March 2023. According to PharmaTrac, sales growth for semaglutide has slowed to 12% in May from 88% in April, as the initial rush of patients has subsided. The slowdown is attributed to several factors, including the original patent holder Novo Nordisk reducing prices for its products, which diminishes the price advantage of generics. Doctors have noted that the initial enthusiasm has waned, with many patients preferring the original semaglutide products due to only a slight price difference. The market, valued at over ₹1,900 crore, is primarily driven by semaglutide and tirzepatide, which together account for over 90% of sales. Despite fears of cannibalization, tirzepatide's sales have rebounded to ₹136 crore in May, showing its strength in the market. Experts predict that growth in the generic semaglutide sector will be gradual, requiring improved physician training and patient counselling over the next one to two years.